References
- Global topical drug delivery analysis, companies profiles, size, share, growth, trends and forecast to 2024. www.researchandmarkets.com/research/r4wqn2/global_topical.
- Drug delivery infusion systems–medical devices pipeline assessment, 2017. www.reportbuyer.com/product/3984749/drug-delivery-infusion-systems-medical-devices-pipeline-assessment-2017.html.
- Partnerships in drug delivery . http://theconferenceforum.org/conferences/partners-in-drug-delivery/overview/.
- BioTime, Inc. Announces pricing of $25.0 million public offering of common stock. http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-newsArticle&ID=2306546.
- E Ink and LTS partner develop smart patch to improve medical management. www.eink.com/news.html?type=releasedetail&id=411&year=2017&page=1.
- LEO Science & Tech Hub announces a collaboration with Elektrofi for formulation technology to improve dermatological drug delivery. http://leo-scitech.com/newspost/leo-science-tech-hub-announces-collaboration-elektrofi-formulation-technology-improve-dermatological-drug-delivery/.
- Vetter to expand its secondary packaging service capacity to meet rising demands (2017). www.vetter-pharma.com/en/news-events/news/secondary-packaging-service-expansion.
- Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases (2017). http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1044319.
- US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with Type 2 diabetes (2017). www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-231017.html.
- Tandem diabetes care to provide all t:slim X2 Insulin Pump Features approved in 2018 to users at no cost and expands existing Dexcom welcome offer for Animas customers (2017). www.businesswire.com/news/home/20171024006695/en/Tandem-Diabetes-Care-Provide-tslim-X2-Insulin.
- Kala Pharmaceuticals submits new drug application to U.S. Food and Drug Administration for INVELTYS™ (KPI-121 1%). http://investors.kalarx.com/phoenix.zhtml?c=254596&p=irol-newsArticle&ID=2311039.
- First patient treated with microscopic beads pre-loaded with a targeted cancer drug. www.ucl.ac.uk/cancer/news/first-patient-treated-beads-targeted-cancer-drug.
- NanOlogy™ announces first patient enrolled in a Phase 2 clinical trial of NanoPac® for treatment of prostate cancer. http://nanology.us/2017/10/16/phase-2-nanopac-trial-prostate-cancer/.
- Eos Biosciences announces issuance of additional U.S. patent for targeted breast cancer therapy. http://eosbiosciences.com/eos-biosciences-announces-issuance-of-additional-u-s-patent-for-targeted-breast-cancer-therapy/.
- Ye BL Zheng R Ruan XJ Zheng ZH Cai HJ . Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway. Biochem. Biophys. Res. Commun. doi:10.1016/j.bbrc.2017.10.156 (2017) ( Epub ahead of print).
- Shi Y LI H Cheng J et al. Entirely oligosaccharide-based supramolecular amphiphiles constructed via host-guest interactions as efficient drug delivery platforms. Chem. Commun. (Camb.)53 (91), 12302–12305 (2017).